Kura Oncology (NASDAQ:KURA) Stock Price Down 4.7% - Should You Sell?

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) were down 4.7% during mid-day trading on Friday . The company traded as low as $5.87 and last traded at $5.95. Approximately 187,067 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 1,182,970 shares. The stock had previously closed at $6.24.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on KURA. Barclays cut their target price on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Wedbush reiterated an "outperform" rating and issued a $36.00 target price on shares of Kura Oncology in a report on Tuesday, April 8th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Kura Oncology in a research note on Monday, April 28th. BTIG Research lowered shares of Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th. Finally, UBS Group lowered their price target on Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $24.50.

Kura Oncology Stock Performance

The firm has a fifty day moving average price of $6.22 and a 200 day moving average price of $8.22. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The stock has a market cap of $480.49 million, a PE ratio of -2.35 and a beta of 0.50.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to analyst estimates of $39.08 million. Research analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors have recently bought and sold shares of the business. Barclays PLC raised its position in Kura Oncology by 104.5% during the third quarter. Barclays PLC now owns 165,484 shares of the company's stock valued at $3,234,000 after acquiring an additional 84,563 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Kura Oncology during the 4th quarter valued at about $436,000. Moody Aldrich Partners LLC grew its holdings in Kura Oncology by 42.3% in the 4th quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company's stock valued at $1,251,000 after buying an additional 42,712 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Kura Oncology by 11.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company's stock valued at $144,000 after purchasing an additional 1,750 shares during the period. Finally, Jennison Associates LLC purchased a new position in Kura Oncology in the fourth quarter worth approximately $623,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.